SCHEMBL4864023

SCHEMBL4864023

Fc1ccccc1CNc1nc(-c2ccccc2)nc2ccccc12

nearest known ligand 0.80

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE5A O76074 12/20 0.71
MEN1 O00255 4/20 0.69
KMT2A Q03164 4/20 0.69
MAPT P10636 3/20 0.69
LMNA P02545 1/20 0.69
GBA1 P04062 1/20 0.68
ATM Q13315 1/20 0.68
POLB P06746 4/20 0.60
MAPK1 P28482 2/20 0.60
REN P00797 1/20 0.59
PTGS1 P23219 1/20 0.58
TBXAS1 P24557 1/20 0.58
PTGS2 P35354 1/20 0.58
ALDH1A1 P00352 2/20 0.57
CYP1A2 P05177 1/20 0.57
CYP3A4 P08684 1/20 0.57
CYP2D6 P10635 1/20 0.57
CYP2C9 P11712 1/20 0.57
CYP2C19 P33261 1/20 0.57
NPSR1 Q6W5P4 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1062755 0.87 MEN1 (0.70) PDE5AMEN1KMT2AMAPTLMNA
SCHEMBL4868144 0.87 MEN1 (0.70) PDE5AMEN1KMT2AMAPTLMNA
SCHEMBL4863157 0.86 PDE5A (0.69) PDE5AMEN1KMT2AMAPTLMNA
SCHEMBL4867676 0.83 PDE5A (0.71) PDE5AMEN1KMT2AMAPTLMNA
SCHEMBL4864159 0.83 PDE5A (1.00) PDE5AMEN1KMT2AMAPTLMNA
SCHEMBL4864646 0.83 PDE5A (0.67) PDE5AMEN1KMT2AMAPTLMNA
SCHEMBL2583554 0.82 MEN1 (1.00) PDE5AMEN1KMT2AMAPTLMNA
SCHEMBL1083763 0.81 PDE5A (1.00) PDE5AMEN1KMT2AMAPTLMNA
SCHEMBL4859994 0.80 CYP1A2 (0.81) PDE5AMEN1KMT2AMAPTLMNA
SCHEMBL4866882 0.80 PDE5A (0.83) PDE5AMEN1KMT2AMAPTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080207614-A1 QUINAZOLINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DIABETES AND OBESITY SK CHEMICALS CO., LTD. (KR) 2008-08-28 US claimed
JP-2008526734-A 2008-07-24 JP claimed
EP-1844023-A1 QUINAZOLINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DIABETES AND OBESITY SK CHEMICALS CO., LTD. (KR) 2007-10-17 EP claimed
WO-2006071095-A1 QUINAZOLINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DIABETES AND OBESITY SK CHEMICALS CO., LTD. (KR) 2006-07-06 WO claimed
US-20080207614-A1 QUINAZOLINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DIABETES AND OBESITY SK CHEMICALS CO., LTD. (KR) 2008-08-28 US disclosed
EP-1844023-A1 QUINAZOLINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DIABETES AND OBESITY SK CHEMICALS CO., LTD. (KR) 2007-10-17 EP disclosed
WO-2006071095-A1 QUINAZOLINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DIABETES AND OBESITY SK CHEMICALS CO., LTD. (KR) 2006-07-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080207614-A1 QUINAZOLINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DIABETES AND OBESITY GPR119, GCKR, GLP1R PDE5A 204/4885MEN1 3837/4885KMT2A 1662/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.